Evonik, a CDMO for complex oral and parenteral drug products requiring advanced drug delivery solutions, launched EUDRACAP, a functional, ready-to-fill oral capsule designed for use in preclinical trials. EUDRACAP preclinic enteric is a very small size 9h (5.1 mm), technical-grade capsule suitable for passing through the gastrointestinal tract of preclinical animal models. The enteric-coated capsule aims to enable pharmaceutical companies to optimize drug development by reducing cost, time, and variables during preclinical trials. Companies can also move seamlessly from preclinical to clinical and commercial stages using the EUDRACAP platform.

EUDRACAP platform leverages the company’s EUDRAGIT functional coatings for optimized release profiles of oral drug products. Evonik’s system solutions are multi-component offerings across products, technologies and services for development and manufacturing for complex drug products. 

The ready-to-fill capsule can be used for any drug candidate demanding protection from the acid environment in the stomach. EUDRACAP preclinic is available with enteric dissolution profile, as a clear, size 9h capsule. For additional sizes and dissolution profiles, the tailor-made EUDRACAP Select remains an option. 

“Every extra step in the drug development process costs time and adds risk,” said Axel Schroeder, head of global business segment oral drug delivery solutions at Evonik Health Care. The latest addition to our EUDRACAP platform is an easy way for our customers to reduce complexity and streamline the whole development process. We look forward to seeing the positive impact in the industry and patients it serves.”